mesalamine has been researched along with Adenomatous Polyposis Coli in 5 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Adenomatous Polyposis Coli: A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The authors found that the treatment showed slightly adverse events in FAP patients." | 2.90 | Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients. ( Abe, T; Doyama, H; Ezoe, Y; Ishikawa, H; Mutoh, M; Nakajima, T; Sakai, T; Takeuchi, Y; Wakabayashi, K, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishikawa, H | 2 |
| Mutoh, M | 2 |
| Sato, Y | 1 |
| Doyama, H | 2 |
| Tajika, M | 1 |
| Tanaka, S | 1 |
| Horimatsu, T | 1 |
| Takeuchi, Y | 2 |
| Kashida, H | 1 |
| Tashiro, J | 1 |
| Ezoe, Y | 2 |
| Nakajima, T | 2 |
| Ikematsu, H | 1 |
| Hori, S | 1 |
| Suzuki, S | 1 |
| Otani, T | 1 |
| Takayama, T | 1 |
| Ohda, Y | 1 |
| Mure, K | 1 |
| Wakabayashi, K | 2 |
| Sakai, T | 2 |
| Lynch, PM | 1 |
| Abe, T | 1 |
| Galatola, M | 1 |
| Miele, E | 1 |
| Strisciuglio, C | 1 |
| Paparo, L | 1 |
| Rega, D | 1 |
| Delrio, P | 1 |
| Duraturo, F | 1 |
| Martinelli, M | 1 |
| Rossi, GB | 1 |
| Staiano, A | 1 |
| Izzo, P | 1 |
| De Rosa, M | 1 |
| Rubin, DT | 1 |
| Cruz-Correa, MR | 1 |
| Gasche, C | 1 |
| Jass, JR | 1 |
| Lichtenstein, GR | 1 |
| Montgomery, EA | 1 |
| Riddell, RH | 1 |
| Rutter, MD | 1 |
| Ullman, TA | 1 |
| Velayos, FS | 1 |
| Itzkowitz, S | 1 |
1 review available for mesalamine and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; I | 2008 |
2 trials available for mesalamine and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control St | 2021 |
Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients.
Topics: Adenomatous Polyposis Coli; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Co | 2019 |
2 other studies available for mesalamine and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Low-dose aspirin and mesalazine for patients with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Aspirin; Chemoprevention; Colectomy; Double-Blind Method; Humans; Mesala | 2021 |
Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis.
Topics: Adenomatous Polyposis Coli; Age of Onset; Anti-Infective Agents; Azathioprine; beta Catenin; Biomark | 2013 |